Salvatore Grisanti

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz et al. · The Lancet · 2023 · 372 citations

Ocular Disease, Ophthalmology, Age-related Diseases +4

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

Arshad M. Khanani, Sunil Patel, Giovanni Staurenghi et al. · The Lancet · 2023 · 263 citations · Full text

Clinical Epidemiology, Clinical Trials, Geographic Atrophy +5

CCR3 is a target for age-related macular degeneration diagnosis and therapy

Atsunobu Takeda, Judit Baffi, Mark E. Kleinman et al. · Nature · 2009 · 249 citations · Full text

Ocular Disease, Ophthalmology, Experimental Ophthalmology +5

Intracameral Bevacizumab for Iris Rubeosis

Salvatore Grisanti, S. Biester, Swaantje Peters et al. · American Journal of Ophthalmology · 2006 · 192 citations

Medicine, Ocular Disease, Intracameral Bevacizumab +1

Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn

Efdal Yoeruek, Focke Ziemssen, Sigrid Henke‐Fahle et al. · Acta Ophthalmologica · 2007 · 169 citations · Full text